Nektar Therapeutics Shares Surge on $90M Jury Award Against Eli Lilly

Key Facts

1Nektar Therapeutics shares rose following a jury verdict awarding the company $90 million in damages in a legal dispute against Eli Lilly.

Nektar Therapeutics shares rose following a jury verdict awarding the company $90 million in damages in a legal dispute against Eli Lilly. Investing.com reported that the jury found in favor of Nektar regarding contractual or intellectual property claims against Eli Lilly.

NKTR closed at $59.38 on September 24, 2026, with the stock reaching a day high of $61.79 and a low of $56.21. The $90 million award represents a material cash infusion for the biotech firm and provides legal validation of its claims.